Professor Robert Clarke
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- China Kadoorie Biobank
- HPS: Heart Protection Study
- PROCARDIS Sibling-pair Studies of Genetic Determinants of MI
- Re-survey and Follow-up of 1970 Whitehall Study
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Improved prediction of fracture risk leveraging a genome-wide polygenic risk score
Lu T. et al, (2021), Genome Medicine, 13
Stroke risk prediction using machine learning: a prospective cohort study of 0.5 million Chinese adults
CLARKE R. et al, (2021), Journal of the American Medical Informatics Association
Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults.
Gnatiuc L. et al, (2021), Eur J Prev Cardiol
Characterisation, identification, clustering, and classification of disease.
Webster AJ. et al, (2021), Sci Rep, 11
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612